Downregulation of p53 has already been observed in the course of acquired resistance to EGFR targeting drugs in lung cancer cell lines, and reconstitution of p53 resulted in a resensitization of these cells to the drugs the cells were adapted to [31,32]. The gene discussed is EGFR; the disease is lung cancer.